Problems in interpreting active control equivalence trials

References

• Freston , J. 1986 . Dose‐ranging in clinical trials: rationale and proposed use with placebo or active controls . American Journal of Gastroenterology , 81 (5) : 307 – 311 .
   PubMed Web of Science ®Google Scholar
• Glassner , S.P. , Clark , P.I. , Lipicky , R.J. , Hubbard , J.M. and Yusuf , S. 1991 . Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials . Journal of the American Medical Association , 265 (12) : 1550 – 1554 .
   Web of Science ®Google Scholar
• Gram , L.F. 1994 . Fluoxetine . New England Journal of Medicine , 331 (20) : 1354 – 1361 .
   PubMed Web of Science ®Google Scholar
• Lasagna , L. 1979 . Editorial: placebos and controlled trials under attack . British Journal of Clinical Pharmacology , 15 (6) : 373 – 374 .
   Web of Science ®Google Scholar
• Prien , R.F. 1988 . Methods and models for placebo use in pharmacotherapeutic trials . Psychopharmacology Bulletin , 24 (l) : 4 – 8 .
   Google Scholar
• Rothman , K.J. and Michels , K.B. 1994 . The continued unethical use of placebo controls. New . England Journal of Medicine , 331 (6) : 394 – 398 .
   PubMed Web of Science ®Google Scholar
• Temple , R. 1982 . Government viewpoint of clinical trials . Drug Information Journal , Jan/June : 10 – 17 .
   Google Scholar
• Temple , R. 1983 . Difficulties in evaluating positive control trials . Proceedings of the American Statistical Association , : 1 – 7 . Biopharmaceutical Section
   Google Scholar
• Temple , R. 1994 . Special study designs: early escape, enrichment, studies in non‐responders . Communications in Statistics , 23 (2) : 499 – 531 .
   Google Scholar